S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 170 participants.

Also called NCT03226340

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 170 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03226340
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03226340. Randomized; no masking; primary purpose treatment. Start 2015-12-02 (actual); primary completion 2018-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
Condition
Essential Hypertension
Intervention (Drug)
S-amlodipine 2.5mg + Chlorthalidone 25mg
Intervention (Drug)
S-amlodipine 2.5mg + Telmisartan 40mg
Lead sponsor
Seoul National University Bundang Hospital (class: other)
Collaborator
Hanlim Pharm. Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03226340
Content hash
ba52eaf3c1f3eeb3cb1cb492642cce503856ae7d658dad32351dbfa5f9ff9887